March 2023: Peter MacCallum Cancer Center (Peter Mac) muAustralia neCartherics Pty Ltd vakapinda muchibvumirano chekudyidzana chekuvandudza chirongwa (CDPA) chekugadzira CTH-002 yekurapa gomarara reovarian.
Muedzo wekiriniki uchaitwa naPeter Mac ichave nguva yekutanga CAR-T cell therapy chigadzirwa chine genetic modifications yakabatanidzwa muCTH-004 yakaedzwa muvanhu.
Kenza yeOvarian ndiyo inouraya zvakanyanya gomarara revakadzi muAustralia, ichiuraya vanopfuura chiuru pagore. Nehuwandu hwemakore mashanu ekupona kwe1,000% chete, pane kudikanwa kwekukurumidzira kwetsvagiridzo kupa avo vakaonekwa mukana uri nani wekupona.
Simon Harrison, director weCentre of Excellence in Cellular immunotherapy Peter Mac, akati: "CAR-T-cell therapy ine simba immunotherapy iyo yakasarudzika yakasarudzika kumurwere wega wega uye iyo inoronga zvakare maT-seli avo kurwisa cancer yavo.
“It has emerged as a new treatment paradigm in gomarara reropa where it can produce complete responses, meaning their blood cancer has disappeared, in patients who have exhausted all other treatment options. The Centre of Excellence in Cellular Immunotherapy at Peter Mac is part of an international effort to expand CAR T-cell kurapa kupfuura kenza yeropa, uye isu tinofara kuve tichishandira pamwe neCartherics pane iyi yekutanga-mu-munhu yekiriniki kuyedzwa kwegomarara reovarian.
Alan Trounson, CEO of Cartherics, said: “There are many patients needing help to control ovarian kenza and CAR-T therapy could be a game changer for them. It is our priority to ensure this potential therapy is tested in kliniki miedzo kukurumidza kukuru."
Cartherics board advisor, Heather Hawkins said: “As an ovarian akapona kenza and patient advocate, I am truly grateful for the vision, skill and dedication of the Cartherics team who are working tirelessly – seeking to improve the survival rates and the quality of life of women diagnosed with ovarian cancer. This announcement brings a real sense of progress and hope in this space.”
Vanopfuura 80% yevarwere vekenza ye ovarian vakatanga kuvhiyiwa kwakabudirira uye kurapwa vanowana kudzokorora.
Zvinangwa zvekutanga zvekutsvagisa kwakabatana kugadzira CTH-004 pachiyero chekiriniki uye kuita chikamu I chekiriniki yekuyedza. Chirongwa ichi chichatungamirwa neCentre of Excellence muCellular Immunotherapy paPeter Mac, ukuwo kugadzira kuchiitwa nevanoshanda naPeter Mac vanogadzira, Cell Therapies Pty Ltd.
Muedzo wekiriniki uchatanga kunyoresa varwere vatanhatu kusvika gumi nevaviri vane kenza yeovarian avo vasati vamborapwa chemotherapy vakatadza. Chinangwa chikuru chechirongwa ichi chekiriniki ndechekuongorora kuchengetedzwa kweCTH-004 muhuwandu hwevarwere.
Cartherics naPeter Mac nguva pfupi yadarika vakazivisa kudyidzana kweCTH-001, imwe autologous CAR-T chigadzirwa chakagadzirwa neCartherics. Vanoshanda navo vakabvumirana, zvichibva pane preclinical data, kuti Peter Mac aise pfungwa dzake paCTH-004.
Nezvegomarara reovarian
Ovarian cancer is a disease in which abnormal cell growth in one or both ovaries leads to the development of cancer. Approximately 314,000 new ovarian cancer cases and 207,000 deaths occurred globally in 2020.
Mumatanho ayo ekutanga, gomarara reovarian rinowanzo asymptomatic uye rinowanzo onekwa panguva yekupedzisira. Kuvhiya uye chemotherapy ndiyo inowanzo rapwa, ingave yega kana musanganiswa. Vanopfuura 80% yevarwere vekenza ye ovarian vakatanga kuvhiyiwa kwakabudirira uye kurapwa vanowana kudzokorora.
Nezve Peter MacCallum Cancer Center
Peter MacCallum Cancer Center inzvimbo yepasi rose yekutsvagisa gomarara, dzidzo, uye nzvimbo yekurapa, pamwe chete neAustralia sevhisi yehutano yeveruzhinji yakazvipira chete kukuchengetedza cancer. Nzvimbo iyi ine vanhu zviuru zvitatu nemazana matatu, kusanganisira vanopfuura mazana manomwe nemakumi mashanu varabhoritari nevatsvaguri vekiriniki, vese vakazvipira kupa marapirwo ari nani egomarara, kutarisirwa, uye kurapwa.
Iyo Center of Excellence muCellular Immunotherapy paPeter Mac inotsigira, inovandudza, uye inoshandura novel cell uye gene kurapwa vachishandisa vagadziri vayo vakamisikidzwa uye vanogadzira vanobatana navo, vakaita seCell Therapies Pty Ltd, kugonesa kushandiswa kwezvigadzirwa izvi mumakiriniki ekuedzwa kwevarwere vegomarara.
Uyezve, kambani iri kugadzira autologous CAR-T masero ekurapa. Aya anoshandisa masero eT akagadziridzwa kubva ku immune system yemurwere anoshanda kurwisa cancer yemurwere maseru. CTH-004 inogadzirwa ne genetically modifying murwere T masero kuisa chimeric antigen receptor (CAR) kunanga mucherechedzo (TAG-72) pamasero egomarara reovarian uye kudzima majini anobatanidzwa muT cell function kudzvinyirira.
CAR T-Cell kurapa muChina yakakura nekukurumidza, uye parizvino kune anopfuura mazana manomwe nemakumi mashanu ekiriniki miedzo yekiriniki iri kuitwa muChina pamhando dzakasiyana dzegomarara.
